Early detection of cardiotoxicity by 2D and 3D deformation imaging in patients receiving chemotherapy

Abstract

The aim of the present study was to find out whether early cardiac changes in patients receiving chemotherapy can be detected by the conventional and deformation parameters of 2D and 3D echocardiography. Twenty-five healthy subjects with normal regional left ventricular function (group 1) and 25 patients receiving chemotherapy (group 2) underwent 2D and 3D transthoracic echocardiography (Toshiba Artida Medical System). All patients (group 2) were examined before and during cardiotoxic chemotherapy at a 3-month follow-up. Left ventricular volumes, ejection fraction, muscle mass, global longitudinal, global radial, global circumferential strain, and rotation were analyzed with 2D and 3D echocardiography, while twist and time-to-peak-intervals were analyzed with 3D echocardiography. For left ventricular volumes and muscle mass, no significant differences were seen between the two study groups (P<0.05). According to our results, myocardial dysfunction induced by cardiotoxic chemotherapy can be detected by 2D global radial strain. Detecting myocardial dysfunction by global longitudinal and circumferential strain requires more than 3 months follow-up. Changes in rotation, twist or time-to-peak intervals could not be verified at the 3-month follow-up in the present study. 2D global radial strain seems to be the most sensitive and robust parameter to detect early myocardial damage during chemotherapy. 3D echocardiography is not yet an established method to detect myocardial damage in clinical practice due to lower spatial and temporal resolution.

3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin’s lymphoma

“…Compared to 2D echocardiography, 3DE has better intra- and inter- observer variability, and test–retest variability, and allows a more accurate assessment of LV volumes and ejection fraction, with better agreement with cardiac magnetic resonance (CMR), considered the “gold standard” 2 , 9 . In cancer patients, 3D LVEF is more sensitive and robust in detecting anthracyclines-induced cardiotoxicity in patients with different forms of solid or hematological tumors 10 , 11 .…”

Possibilities of modern echocardiographic technologies in the early diagnosis of the cardiotoxic effect of chemotherapy drugs anthracycline series in cancer patients

“…В ряде исследований было показано, что данная технология позволяет диагностировать раннюю субклиническую дисфункцию ЛЖ [24][25][26][27][28], в том числе непосредственно на фоне противоопухолевой терапии [26,29,30].…”

Noninvasive early detection of anthracycline‐induced cardiotoxicity in patients with hematologic malignancies using the phased tracking method

“…They are extremely effective drugs for the treatment of leukemia and a wide variety of solid tumors. In patients undergoing anthracycline therapy, dose-dependent myocardial impairment has been described in 23-74% of cases, with a high incidence of [2,3,[17][18][19][20][21]. In contrast, there are no evidence-based guidelines for monitoring cardiotoxicity in adult patients with cancer [22,23].…”